DiabetOmics Inc. will use the funds to manufacture its point-of-care tests for pre-eclampsia and saliva monitoring for diabetes.
DiabetOmics Inc. will use the funds to manufacture its point-of-care tests for pre-eclampsia and saliva monitoring for diabetes.
According to a filing with the U.S. Securities and Exchange Commission, the funding round could go as high as $15 million.
CEO Dr. Srinivasa Nagalla said he expects to ship the products by the end of the first quarter of 2015.
Read more at Portland Business Journal
